Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
Authors
Keywords
-
Journal
Nature Communications
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-29
DOI
10.1038/s41467-020-16142-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Early ctDNA dynamics as a surrogate for progression free survival in advanced breast cancer in the BEECH trial
- (2019) S Hrebien et al. ANNALS OF ONCOLOGY
- PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
- (2019) Constantia Pantelidou et al. Cancer Discovery
- BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
- (2019) Timo Reisländer et al. Nature Communications
- Interferon Signaling is Diminished with Age and is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer
- (2019) Jaclyn Sceneay et al. Cancer Discovery
- Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study
- (2019) Johan Staaf et al. NATURE MEDICINE
- Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance
- (2019) Alex Pearson et al. CLINICAL CANCER RESEARCH
- RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
- (2018) C Cruz et al. ANNALS OF ONCOLOGY
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
- (2018) Andrew Tutt et al. NATURE MEDICINE
- Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
- (2018) Ben O’Leary et al. Nature Communications
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
- (2018) Marta Castroviejo‐Bermejo et al. EMBO Molecular Medicine
- PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer
- (2018) Roman M. Chabanon et al. JOURNAL OF CLINICAL INVESTIGATION
- Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer
- (2017) Robert W Mutter et al. JOURNAL OF PATHOLOGY
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer
- (2017) Paz Polak et al. NATURE GENETICS
- HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
- (2017) Helen Davies et al. NATURE MEDICINE
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Signatures of DNA-Repair Deficiencies in Breast Cancer
- (2017) Nicholas C. Turner NEW ENGLAND JOURNAL OF MEDICINE
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
- (2016) M. L. Telli et al. CLINICAL CANCER RESEARCH
- Landscape of somatic mutations in 560 breast cancer whole-genome sequences
- (2016) Serena Nik-Zainal et al. NATURE
- Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease
- (2015) Eleonor Olsson et al. EMBO Molecular Medicine
- Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105
- (2015) Melinda L. Telli et al. JOURNAL OF CLINICAL ONCOLOGY
- TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
- (2015) Steven J. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Robust enumeration of cell subsets from tissue expression profiles
- (2015) Aaron M Newman et al. NATURE METHODS
- Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
- (2015) Isaac Garcia-Murillas et al. Science Translational Medicine
- HTSeq--a Python framework to work with high-throughput sequencing data
- (2014) S. Anders et al. BIOINFORMATICS
- Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment
- (2014) K. A. T. Naipal et al. CLINICAL CANCER RESEARCH
- Absolute Assignment of Breast Cancer Intrinsic Molecular Subtype
- (2014) Eric R. Paquet et al. JNCI-Journal of the National Cancer Institute
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- STAR: ultrafast universal RNA-seq aligner
- (2012) Alexander Dobin et al. BIOINFORMATICS
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
- (2012) V Abkevich et al. BRITISH JOURNAL OF CANCER
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
- (2012) T. Popova et al. CANCER RESEARCH
- Mutational Processes Molding the Genomes of 21 Breast Cancers
- (2012) Serena Nik-Zainal et al. CELL
- Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
- (2012) Nicolai J. Birkbak et al. Cancer Discovery
- FLASH: fast length adjustment of short reads to improve genome assemblies
- (2011) T. Magoc et al. BIOINFORMATICS
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
- (2010) M. Graeser et al. CLINICAL CANCER RESEARCH
- Homologous recombination in DNA repair and DNA damage tolerance
- (2008) Xuan Li et al. CELL RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started